Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug.

Journal of the National Cancer Institute

Volumn 103, Issue 3, 2011, Pages

  Tuma, Rabiya S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MAP3K8 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLX 4032; RAF PROTEIN; SULFONAMIDE;

CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MELANOMA; METABOLISM; METASTASIS; MUTATION; NOTE; ONCOGENE RAS; SIGNAL TRANSDUCTION; TIME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; INDOLES; MAP KINASE KINASE KINASES; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONAMIDES; TIME FACTORS;

EID: 79952475511     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr016     Document Type: Note

References (0)